SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

20201,420 citationsJournal Articlegreen Open Access

Authors

Peter Chen · Norwegian Womens Public Health Association

Ajay Nirula · Norwegian Womens Public Health Association

Barry N. Heller · Norwegian Womens Public Health Association

Robert Gottlieb · Norwegian Womens Public Health Association

Joseph Boscia · Norwegian Womens Public Health Association

Jason Morris · Norwegian Womens Public Health Association

Gregory Huhn

Abstract

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).

Topics & Keywords

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies Long-Term Effects of COVID-19

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 3, pp. 229-237

DOI: 10.1056/nejmoa2029849

Field-Weighted Citation Impact: 32.03